Trial Profile
Effect of Topical Aqueous Suppressants on Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration (AMD), Retinal Vein Occlusions (RVO) or Diabetic Macular Edema (DME).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dorzolamide/timolol (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Therapeutic Use
- 17 Apr 2018 Status changed from recruiting to completed.
- 17 Feb 2017 Status changed to recruiting.
- 14 Oct 2015 New trial record